1062 related articles for article (PubMed ID: 23234619)
1. Urodynamic effects of once daily tadalafil in men with lower urinary tract symptoms secondary to clinical benign prostatic hyperplasia: a randomized, placebo controlled 12-week clinical trial.
Dmochowski R; Roehrborn C; Klise S; Xu L; Kaminetsky J; Kraus S
J Urol; 2013 Jan; 189(1 Suppl):S135-40. PubMed ID: 23234619
[TBL] [Abstract][Full Text] [Related]
2. Urodynamic effects of once daily tadalafil in men with lower urinary tract symptoms secondary to clinical benign prostatic hyperplasia: a randomized, placebo controlled 12-week clinical trial.
Dmochowski R; Roehrborn C; Klise S; Xu L; Kaminetsky J; Kraus S
J Urol; 2010 Mar; 183(3):1092-7. PubMed ID: 20092847
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of tadalafil once daily in the treatment of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: results of an international randomized, double-blind, placebo-controlled trial.
Porst H; Kim ED; Casabé AR; Mirone V; Secrest RJ; Xu L; Sundin DP; Viktrup L;
Eur Urol; 2011 Nov; 60(5):1105-13. PubMed ID: 21871706
[TBL] [Abstract][Full Text] [Related]
4. Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study.
Roehrborn CG; McVary KT; Elion-Mboussa A; Viktrup L
J Urol; 2008 Oct; 180(4):1228-34. PubMed ID: 18722631
[TBL] [Abstract][Full Text] [Related]
5. Tadalafil once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a randomized placebo- and tamsulosin-controlled 12-week study in Asian men.
Yokoyama O; Yoshida M; Kim SC; Wang CJ; Imaoka T; Morisaki Y; Viktrup L
Int J Urol; 2013 Feb; 20(2):193-201. PubMed ID: 22958078
[TBL] [Abstract][Full Text] [Related]
6. Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia.
McVary KT; Roehrborn CG; Kaminetsky JC; Auerbach SM; Wachs B; Young JM; Esler A; Sides GD; Denes BS
J Urol; 2007 Apr; 177(4):1401-7. PubMed ID: 17382741
[TBL] [Abstract][Full Text] [Related]
7. Effects of tadalafil once daily on maximum urinary flow rate in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia.
Roehrborn CG; Chapple C; Oelke M; Cox D; Esler A; Viktrup L
J Urol; 2014 Apr; 191(4):1045-50. PubMed ID: 24445278
[TBL] [Abstract][Full Text] [Related]
8. Tadalafil once daily in the treatment of lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) in men without erectile dysfunction.
Brock G; Broderick G; Roehrborn CG; Xu L; Wong D; Viktrup L
BJU Int; 2013 Nov; 112(7):990-7. PubMed ID: 23937669
[TBL] [Abstract][Full Text] [Related]
9. Hemodynamic effects of once-daily tadalafil in men with signs and symptoms of benign prostatic hyperplasia on concomitant α1-adrenergic antagonist therapy: results of a multicenter randomized, double-blind, placebo-controlled trial.
Goldfischer E; Kowalczyk JJ; Clark WR; Brady E; Shane MA; Dgetluck N; Klise SR
Urology; 2012 Apr; 79(4):875-82. PubMed ID: 22341603
[TBL] [Abstract][Full Text] [Related]
10. Effect of tadalafil once daily on prostate blood flow and perfusion in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia: a randomized, double-blind, multicenter, placebo-controlled trial.
Pinggera GM; Frauscher F; Paduch DA; Bolyakov A; Efros M; Kaminetsky J; Da Pozzo L; Esler A; Cox D
Urology; 2014 Aug; 84(2):412-9. PubMed ID: 24938580
[TBL] [Abstract][Full Text] [Related]
11. Time to onset of clinically meaningful improvement with tadalafil 5 mg once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: analysis of data pooled from 4 pivotal, double-blind, placebo controlled studies.
Oelke M; Shinghal R; Sontag A; Baygani SK; Donatucci CF
J Urol; 2015 May; 193(5):1581-9. PubMed ID: 25437533
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of the coadministration of tadalafil once daily with finasteride for 6 months in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia.
Casabé A; Roehrborn CG; Da Pozzo LF; Zepeda S; Henderson RJ; Sorsaburu S; Henneges C; Wong DG; Viktrup L
J Urol; 2014 Mar; 191(3):727-33. PubMed ID: 24096118
[TBL] [Abstract][Full Text] [Related]
13. Direct effects of tadalafil on lower urinary tract symptoms versus indirect effects mediated through erectile dysfunction symptom improvement: integrated data analyses from 4 placebo controlled clinical studies.
Brock GB; McVary KT; Roehrborn CG; Watts S; Ni X; Viktrup L; Wong DG; Donatucci C
J Urol; 2014 Feb; 191(2):405-11. PubMed ID: 24096120
[TBL] [Abstract][Full Text] [Related]
14. Effects of tadalafil on storage and voiding function in patients with male lower urinary tract symptoms suggestive of benign prostatic hyperplasia: A urodynamic-based study.
Matsukawa Y; Majima T; Matsuo K; Funahashi Y; Kato M; Yamamoto T; Gotoh M
Int J Urol; 2018 Mar; 25(3):246-250. PubMed ID: 29164680
[TBL] [Abstract][Full Text] [Related]
15. Urodynamics and safety of the β₃-adrenoceptor agonist mirabegron in males with lower urinary tract symptoms and bladder outlet obstruction.
Nitti VW; Rosenberg S; Mitcheson DH; He W; Fakhoury A; Martin NE
J Urol; 2013 Oct; 190(4):1320-7. PubMed ID: 23727415
[TBL] [Abstract][Full Text] [Related]
16. Effects of tadalafil on lower urinary tract symptoms secondary to benign prostatic hyperplasia in men with or without erectile dysfunction.
Broderick GA; Brock GB; Roehrborn CG; Watts SD; Elion-Mboussa A; Viktrup L
Urology; 2010 Jun; 75(6):1452-8. PubMed ID: 20163842
[TBL] [Abstract][Full Text] [Related]
17. Tadalafil 5 mg once-daily therapy for men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: results from a randomized, double-blind, placebo-controlled trial carried out in Japan and Korea.
Takeda M; Yokoyama O; Lee SW; Murakami M; Morisaki Y; Viktrup L
Int J Urol; 2014 Jul; 21(7):670-5. PubMed ID: 24571205
[TBL] [Abstract][Full Text] [Related]
18. Monotherapy with tadalafil or tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo-controlled clinical trial.
Oelke M; Giuliano F; Mirone V; Xu L; Cox D; Viktrup L
Eur Urol; 2012 May; 61(5):917-25. PubMed ID: 22297243
[TBL] [Abstract][Full Text] [Related]
19. Tadalafil - a therapeutic option in the management of BPH-LUTS.
Carson CC; Rosenberg M; Kissel J; Wong DG
Int J Clin Pract; 2014 Jan; 68(1):94-103. PubMed ID: 24341303
[TBL] [Abstract][Full Text] [Related]
20. Treatment satisfaction with tadalafil or tamsulosin vs placebo in men with lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH): results from a randomised, placebo-controlled study.
Oelke M; Giuliano F; Baygani SK; Melby T; Sontag A
BJU Int; 2014 Oct; 114(4):568-75. PubMed ID: 24612148
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
